Foundational Pharmacy Strategies

a MacroHealth company

Claim Review

Reporting Range: 05/01/2025 - 04/30/2026

Confidential – Proprietary Information of Foundational Pharmacy Strategies, LLC
Copyright © 2025 Foundational Pharmacy Strategies, LLC. All Rights Reserved.
This document contains confidential and proprietary information intended solely for the recipient. Unauthorized copying, distribution, or use is strictly prohibited.

Pharmacy Dashboard Report

Current: 05/01/2025 - 04/30/2026

Foundational Pharmacy Strategies
a MacroHealth company

Observations & FPS Actions:

Total Cost PMPM of $71.35 is well below the $123.21 national benchmark. Total cost has remained consistent quarter-over-quarter. The plan is considered to be performing well in their PBM experience.

Specialty spend is 1% of claims yet 38% of plan paid. Anti-inflammatory drugs make up at least 23% of plan spend within this claims set. TrueScripts is known for their 340b program that may provide additional savings to the plan outside the claim experience in the form of a check.


- For Skyrizi and Rinvoq, consider low-cost biosimilar options before the high-cost brands when medically appropriate. Determine if TrueScripts prefers this in their criteria for use. If medically necessary to continue, review day supply and confirm pricing as some anomolies appearred in the data.
- Transition to Humira biosimilar is already in place. Patient on Humira transferred to biosimilar in January of 2026 which resulted in >$6,000/claim savings.

In non-specialty, brand copay program is in place. The generic dispensing rate of 93% is excellent. Diabetes supplies and insulins comprise at least 11% of plan spend.


- Review current process for validating uncontrolled diabetes and engagement of comprehensive care support. GLP-1 spend fell just shy of the top three therapeutic classes but is a contributor to overall diabetes spend.

* Copay assistance programs are in place but not included in the report


Per Member Per Month Costs



Plan Cost PMPM - Specialty/Non-Specialty



Top 10 Patients by Spend Account for 33% of Total Costs



Confidential – Proprietary Information of Foundational Pharmacy Strategies, LLC
Copyright © 2025 Foundational Pharmacy Strategies, LLC. All Rights Reserved.
This document contains confidential and proprietary information intended solely for the recipient. Unauthorized copying, distribution, or use is strictly prohibited.

Specialty Therapeutic Breakdown

Condition	Drug Name	Unique Patients	No of Claims	Total Plan Paid	% Total Plan Paid
Antirheumatic - Enzyme Inhibitors	Rinvoq	3	18	$128,703	10%
...	...	...	...	...	...
...	...	...	...	...	...
...	...	...	...	...	...
...	...	...	...	...	...
Total Top 5		**3**	**18**	**$128,703**	**10%**
Total Overall		**3**	**18**	**$128,703**	**10%**
Inflammatory Bowel Agents	Skyrizi	1	4	$65,021	5%
	Omvoh	1	7	$22,027	1%
...	...	...	...	...	...
...	...	...	...	...	...
...	...	...	...	...	...
Total Top 5		**2**	**11**	**$87,049**	**7%**
Total Overall		**2**	**11**	**$87,049**	**7%**
Anti - Tnf - Alpha - Monoclonal Antibodies	Humira (2 Pen)	1	9	$61,029	5%
	Adalimumab-aaty (2 Pen)	3	8	$17,380	1%
	Adalimumab-ryvk (2 Pen)	1	3	$2,085	< 1%
	Adalimumab-aaty (1 Pen)	1	1	$1,500	< 1%
...	...	...	...	...	...
Total Top 5		**5**	**21**	**$81,994**	**6%**
Total Overall		**5**	**21**	**$81,994**	**6%**
GRAND TOTAL		**10**	**50**	**$297,746**	**23%**

Confidential – Proprietary Information of Foundational Pharmacy Strategies, LLC
Copyright © 2025 Foundational Pharmacy Strategies, LLC. All Rights Reserved.
This document contains confidential and proprietary information intended solely for the recipient. Unauthorized copying, distribution, or use is strictly prohibited.

Pharmacy Drug Class Review

Current: 05/01/2025 - 04/30/2026

Foundational Pharmacy Strategies
a MacroHealth company

Non-Specialty Therapeutic Breakdown

Condition	Drug Name	Unique Patients	No of Claims	Total Plan Paid	% Total Plan Paid
Sympathomimetics	Trelegy Ellipta	11	75	$51,421	4%
	Breztri Aerosphere	6	20	$13,473	1%
	Albuterol Sulfate HFA	94	240	$6,794	< 1%
	Budesonide-Formoterol Fumarate	6	27	$5,909	< 1%
	Breyna	4	12	$4,735	< 1%
Total Top 5		**102**	**374**	**$82,332**	**6%**
Total Overall		**109**	**455**	**$94,525**	**7%**
Diabetic Supplies	Dexcom G7 Sensor	24	109	$55,323	4%
	Omnipod 5 DexG7G6 Pods Gen 5	5	29	$21,449	1%
	Dexcom G6 Sensor	3	16	$5,576	< 1%
	Dexcom G7 15 Day Sensor	5	7	$3,805	< 1%
	Omnipod 5 DexG7G6 Intro Gen 5	2	2	$1,096	< 1%
Total Top 5		**31**	**163**	**$87,248**	**7%**
Total Overall		**46**	**190**	**$88,553**	**7%**
Insulin	Lantus SoloStar	21	84	$10,839	< 1%
	Toujeo Max SoloStar	4	20	$10,034	< 1%
	HumaLOG KwikPen	3	5	$8,819	< 1%
	Insulin Lispro (1 Unit Dial)	8	21	$4,562	< 1%
	Basaglar KwikPen	5	7	$3,772	< 1%
Total Top 5		**30**	**137**	**$38,026**	**3%**
Total Overall		**37**	**199**	**$49,823**	**4%**
GRAND TOTAL		**165**	**844**	**$232,900**	**18%**

Confidential – Proprietary Information of Foundational Pharmacy Strategies, LLC
Copyright © 2025 Foundational Pharmacy Strategies, LLC. All Rights Reserved.
This document contains confidential and proprietary information intended solely for the recipient. Unauthorized copying, distribution, or use is strictly prohibited.

Claim Summary

Current: 05/01/2025 - 04/30/2026

Foundational Pharmacy Strategies
a MacroHealth company

Agg. Total Claim Summary

Quarters	May - Jul 2025	Aug - Oct 2025	Nov 25 - Jan 26	Feb - Apr 2026	YTD
Member Months	4,809	4,809	4,809	4,809	19,236
Nbr of Unique Patients	653	728	761	750	1,044
Nbr of Claims	3,688	4,084	4,262	4,120	16,154
Claims PMPM	0.77	0.85	0.89	0.86	0.84
Total Cost	$321,206	$321,824	$375,871	$353,653	$1,372,554
Plan Paid	$279,234	$277,360	$331,211	$310,848	$1,198,653
Member Out of Pocket	$41,972	$44,464	$44,660	$42,804	$173,901
Copay Assistance	-	-	-	-	-
Avg. Total Cost per Claim	$87	$79	$88	$86	$85
Total Cost PMPM	$66.79	$66.92	$78.15	$73.53	$71.35
Plan Paid PMPM	$58.06	$57.67	$68.87	$64.63	$62.31
Member OOP PMPM	$8.72	$9.24	$9.28	$8.90	$9.04
Administrative Fees	-	-	-	-	-
Rebates	-	-	-	-	-
Net Plan Paid	-	-	-	-	-
Net Plan Paid PMPM	-	-	-	-	-

Confidential – Proprietary Information of Foundational Pharmacy Strategies, LLC
Copyright © 2025 Foundational Pharmacy Strategies, LLC. All Rights Reserved.
This document contains confidential and proprietary information intended solely for the recipient. Unauthorized copying, distribution, or use is strictly prohibited.

Claim Summary

Current: 05/01/2025 - 04/30/2026

Foundational Pharmacy Strategies
a MacroHealth company

Aggregated Claim Summary - Brand

Quarters	May - Jul 2025	Aug - Oct 2025	Nov 25 - Jan 26	Feb - Apr 2026	YTD
Nbr of Unique Patients	106	126	124	115	253
Nbr of Claims	224	266	279	248	1,017
Total Cost	$100,476	$126,706	$138,917	$124,968	$491,067
Plan Paid	$92,257	$118,043	$129,647	$115,204	$455,151
Member Out of Pocket	$8,219	$8,663	$9,269	$9,764	$35,916
Copay Assistance	-	-	-	-	-
Avg. Total Cost per Claim	$449	$476	$498	$504	$483
Total Cost PMPM	$20.89	$26.34	$28.88	$25.98	$25.52
Plan Paid PMPM	$19.18	$24.54	$26.95	$23.95	$23.66
Member OOP PMPM	$1.70	$1.80	$1.92	$2.03	$1.86
Copay Assistance PMPM	-	-	-	-	-
% of Plan Paid	33%	42%	39%	37%	37%
% of Total Claims	6%	7%	7%	6%	6%

Aggregated Claim Summary - Generic

Quarters	May - Jul 2025	Aug - Oct 2025	Nov 25 - Jan 26	Feb - Apr 2026	YTD
Nbr of Unique Patients	644	719	754	738	1,033
Nbr of Claims	3,444	3,804	3,961	3,842	15,051
Total Cost	$106,648	$106,400	$108,292	$98,872	$420,212
Plan Paid	$74,395	$71,650	$73,757	$67,331	$287,132
Member Out of Pocket	$32,253	$34,751	$34,536	$31,541	$133,080
Copay Assistance	-	-	-	-	-
Avg. Total Cost per Claim	$31	$28	$27	$26	$28
Total Cost PMPM	$22.17	$22.12	$22.51	$20.55	$21.84
Plan Paid PMPM	$15.46	$14.89	$15.33	$14.00	$14.92
Member OOP PMPM	$6.70	$7.22	$7.18	$6.55	$6.91
Copay Assistance PMPM	-	-	-	-	-
% of Plan Paid	26%	25%	22%	21%	23%
% of Total Claims	93%	93%	93%	93%	93%

Aggregated Claim Summary - Specialty

Quarters	May - Jul 2025	Aug - Oct 2025	Nov 25 - Jan 26	Feb - Apr 2026	YTD
Nbr of Unique Patients	14	10	11	18	23
Nbr of Claims	20	14	22	30	86
Total Cost	$114,083	$88,718	$128,662	$129,812	$461,275
Plan Paid	$112,583	$87,668	$127,807	$128,312	$456,370
Member Out of Pocket	$1,500	$1,050	$855	$1,500	$4,905
Copay Assistance	-	-	-	-	-
Avg. Total Cost per Claim	$5,704	$6,337	$5,848	$4,327	$5,364
Total Cost PMPM	$23.72	$18.44	$26.75	$26.99	$23.97
Plan Paid PMPM	$23.41	$18.22	$26.57	$26.68	$23.72
Member OOP PMPM	$0.31	$0.21	$0.17	$0.31	$0.25
Copay Assistance PMPM	-	-	-	-	-
% of Plan Paid	40%	31%	38%	41%	38%
% of Total Claims	< 1%	-	< 1%	< 1%	< 1%

Confidential – Proprietary Information of Foundational Pharmacy Strategies, LLC
Copyright © 2025 Foundational Pharmacy Strategies, LLC. All Rights Reserved.
This document contains confidential and proprietary information intended solely for the recipient. Unauthorized copying, distribution, or use is strictly prohibited.

High Cost Claimant Table

Current: 05/01/2025 - 04/30/2026

Foundational Pharmacy Strategies
a MacroHealth company

PBM High-Cost Claimants					
Member	**Noteworthy Drug Class**	**Total Spend**	**% of Plan Spend**	**No. of Claims**	**Notes**
	GASTROINTESTINAL AGENTS - MISC.	$68,228	5%	75	Noteworthy Drug: **Skyrizi** is likely being used for ulcerative colitis or Crohn's disease due to the every 56-day supply. **Determine if this medication is being dispensed by a 340b pharmacy program offered by TrueScripts. The net cost may be reduced and not visible within the claims file.**
	ANALGESICS - ANTI-INFLAMMATORY	$65,276	5%	95	Noteworthy Drug: **Rinvoq** is used for specialty inflammatory conditions. Other lower cost biologics are available to treat those conditions, but once a patient is stable, it can be challenging to change therapies. The patient has an unusual 90-day supply submitted in March but followed by 30-days in April. **Determine if this medication is being dispensed by a 340b pharmacy program offered by TrueScripts. The net cost may be reduced and not visible within the claims file. Determine the cause for the unusual 90-day fill.**
	ANALGESICS - ANTI-INFLAMMATORY	$65,023	5%	47	Noteworthy Drug: **Humira** is used for specialty inflammatory conditions. **Monitor for response. The patient changed to the low cost biosimilar in 2026 for a savings estimate of >$6,000/claim or $72,000 annually.**
	ANALGESICS - ANTI-INFLAMMATORY	$63,784	5%	119	Noteworthy Drug: **Rinvoq** is used for specialty inflammatory conditions. Other lower cost biologics are available to treat those conditions, but once a patient is stable, it can be challenging to change therapies. The patient has an unusual first fill in June 2025 for 150 tablets but all other claims appear as expected. **Determine if this medication is being dispensed by a 340b pharmacy program offered by TrueScripts. The net cost may be reduced and not visible within the claims file. Determine the cause for the unusual first fill.**
	DERMATOLOGICALS	$52,071	4%	25	Noteworthy Drug: **Skyrizi** is used for specialty inflammatory conditions. Other lower cost biologics are available to treat those conditions, but once a patient is stable, it can be challenging to change therapies. The patient has an unusual fill patterns. **The 2025 day supply and fill history are not as expected, but the 2026 fill in April processed with a better than industry expected pricing. Determine if the savings are a result of 340b program at point-of-sale.**
	DERMATOLOGICALS	$49,566	4%	59	Noteworthy Drug: **Dupixent** can be used for a variety of conditions including dermatologic, respiratory, and more. Other lower cost options are available to treat those conditions, but once a patient is stable, it can be challenging to change therapies. **Determine if this medication is eligible for the 340b program.**
	GASTROINTESTINAL AGENTS - MISC.	$28,122	2%	28	Noteworthy Drug: **Omvoh** is for specialty inflammatory conditions. The patient transitioned from Stelara. Determine the treatment failure. **Determine if this medication is being dispensed by a 340b pharmacy program offered by TrueScripts. The net cost may be reduced and not visible within the claims file.**
	ANALGESICS - ANTI-INFLAMMATORY	$21,357	2%	59	Noteworthy Drug: Otezla can be used for specialty inflammatory conditions. The fill quantities are unusual with a 140 day supply then 84 day supply. **Determine if the day supply is accurate. Determine if this medication is potentially in an alternative sourcing program.**
	MEDICAL DEVICES AND SUPPLIES	$18,222	1%	64	Noteworthy Drug: **Omnipod** is for monitoring blood sugar in diabetic patients. The patient has numerous medications and supplies to support diabetic diagnosis.
	ANTIPSYCHOTICS/ANTIMANIC AGENTS	$16,546	1%	173	Noteworthy Drug: Rexulti is for mental health. The patient also had Trintellix. Neither medication has been filled within the last 3 months. The patient has a complex profile with multiple chronic conditions and fill patterns. **Recommend polypharmacy engagement to optimize patient's complex chronic conditions. Leverage pharmacogenomic (PGx) testing is necessary to assist in mental health treatment plan.**

Confidential – Proprietary Information of Foundational Pharmacy Strategies, LLC
Copyright © 2025 Foundational Pharmacy Strategies, LLC. All Rights Reserved.
This document contains confidential and proprietary information intended solely for the recipient. Unauthorized copying, distribution, or use is strictly prohibited.